SC
EW icon

Stempoint Capital’s Edwards Lifesciences EW Stock Holding History

Stempoint Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
+14,588
New +$1.2M 0.22% 65

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Stempoint Capital's EW Position: Q1 2026 in Review

Stempoint Capital opened a new position in Edwards Lifesciences (EW) in Q1 2026: 14,588 shares worth $1.17M. The stake represents 0.22% of the portfolio and ranks #65 among its holdings.

1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Stempoint Capital held 14,588 shares of Edwards Lifesciences worth $1.17M as of Q1 2026.
  • Edwards Lifesciences was a new Stempoint Capital position in Q1 2026.
  • Edwards Lifesciences made up 0.22% of Stempoint Capital's portfolio in Q1 2026, its #65 holding.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.